Start-Up Nation Finder

45 companies were selected

Add smartlist note (optional)

Smartlist name*

Smartlist must have a valid name.

Description (optional)

Hey #USER_FULLNAME#!

Claim #COMPANY_NAME# ’s profile to become an administrator with editing privileges in
#COMPANY_NAME# ’s page on Start-Up Nation Finder

The invitation to claim the profile was originally sent to

Hey #USER_FULLNAME#!

Claim #COMPANY_NAME# ’s profile to become an administrator with editing privileges in
#COMPANY_NAME# ’s page on Start-Up Nation Finder

Please provide us the following information. Note that you need to have an email in this organization in order to claim the profile.

Name*

Work Email* (please provide your email in the organization)

Position*

Notes

I agree to receive Informational Emails from Start-Up Nation Finder as defined in the Privacy Policy and Terms of Use

Already have an account?

Search Was Saved

Home > Companies > NeuroDerm

Claimed by owner • Last Update 8.5.2022 • Suggest Edits • Claim Profile

Claimed by owner

NeuroDerm

Liquid Drug Formula for Parkinson's Disease

Acquired by Mitsubishi Tanabe Pharma Corporation on Jul, 2017

NeuroDerm

www.prnewswire.com • Aug 28, 2019

Phase 3 Clinical Trial Evaluating Continuous Subcutaneous Carbidopa/Levodopa (ND0612) Initiated In The United States For Parkinson's Disease With Motor Fluctuations

globenewswire.com • Jul 24, 2017

NeuroDerm Enters Definitive Agreement to be Acquired by Mitsubishi Tanabe Pharma Corporation for US$1.1 Billion in Cash

www.globes.co.il • Jun 13, 2017

Neuroderm mulls several acquisition offers

www.globes.co.il • Mar 2, 2017

Neuroderm jumps on successful trial results

www.globes.co.il • Jul 16, 2015

NeuroDerm raises $67m in Nasdaq secondary offering

www.globes.co.il • Jul 14, 2015

NeuroDerm ups Nasdaq secondary offering to $58m

www.reuters.com • Dec 30, 2014

http://www.reuters.com/article/2014/12/30/us-neuroderm-study-idUSKBN0K810K20141230

www.globes.co.il • Nov 14, 2014

NeuroDerm Nasdaq IPO disappoints

www.globes.co.il • Nov 3, 2014

NeuroDerm set for $60-82m Nasdaq IPO

NeuroDerm is a clinical-stage pharmaceutical company developing treatments for central nervous system disorders. The company's technology enables new routes of administration for existing drugs that may enhance their efficacy.
NeuroDerm is developing a pipeline of products for patients with moderate-to-severe Parkinson's disease, including a liquid formulation of levodopa/carbidopa (LD/CD). Based on this novel formulation, the company has developed a line of LD/CD products administered through a patch-pump or small belt pump to deliver a continuous, controlled dose of LD/CD.
NeuroDerm's LD/CD line of products includes ND0612L for patients with moderate Parkinson's disease, ND0612H for patients with severe Parkinson's disease, and ND0680 for the small subset of patients with severe Parkinson's disease whose symptoms have advanced to a more acute stage, requiring even higher doses of LD/CD.